Omicron Clouds Novavax’s Delayed COVID-19 Vaccine Debut
After Repeated Delays, Investors Doubt Readiness
Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.
You may also be interested in...
Availability of emergency authorization route in US depends upon lack of 'adequate, approved and available alternatives,' but as more vaccines make their way through the BLA process sponsors may find the EUA door slowly closing.
Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.
The FDA authorized Comirnaty as a booster shot for 12- to 15-year-olds, as J&J's vaccine has shown effectiveness as a booster in Omicron-dominant settings. Meanwhile, Pfizer's Paxlovid won approval in the UK, and Novavax submitted the final data for its vaccine to the FDA.